SK Chemicals, TheraVida deal

TheraVida granted SK Chemicals exclusive rights to develop and commercialize Tolenix ( THVD-201) and THVD-202 in South Korea for overactive bladder (OAB) and urge urinary incontinence. SK Chemicals is responsible for funding the development and commercialization of the compounds, and TheraVida is eligible for milestones upon the submission of an NDA and first sale in South Korea, plus tiered, double-digit royalties. TheraVida declined to disclose details, and SK Chemicals could not be reached for details. ...